Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johann Riedemann

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Biochemical and Biophysical Research Communications|February 27, 2007
Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cellsJohann Riedemann, Muhammad Sohail, Valentine M Macaulay
Biochemical and Biophysical Research Communications|February 20, 2007
The EGF receptor interacts with the type 1 IGF receptor and regulates its stabilityJohann Riedemann, Megumi Takiguchi, Muhammad Sohail, et al.
Immunologic Research|May 30, 2024
Highlighting the role of CD44 in cervical cancer progression: immunotherapy's potential in inhibiting metastasis and chemoresistanceCayleigh de Sousa, Carla Eksteen, Johann Riedemann, et al.
Nucleic Acids Research|March 26, 2003
A simple and cost-effective method for producing small interfering RNAs with high efficacyMuhammad Sohail, Graeme Doran, Johann Riedemann, et al.
Cytokine & Growth Factor Reviews|December 5, 2025
Post COVID-19 pandemic Inflammatory Insights into Cancer: Consequences for immunotherapyCarla Eksteen, Lé-Chandré Asja, Atarah Rass, et al.
Cancer Gene Therapy|October 23, 2004
Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancerMark A Rochester, Johann Riedemann, Giles O Hellawell, et al.
Seminars in Oncology|June 12, 2025
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy responseCarla Eksteen, Johann Riedemann, Frederick H van der Merwe, et al.
The Journal of Biological Chemistry|February 27, 2003
The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcriptErin A Bohula, Amanda J Salisbury, Muhammad Sohail, et al.
BMC Cell Biology|May 17, 2011
Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein CGerrida M Uys, Amsha Ramburan, Benjamin Loos, et al.
Cancer Control : Journal of the Moffitt Cancer Center|June 17, 2024
A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical CancerCarla Eksteen, Johann Riedemann, Atarah M Rass, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Biochemical and Biophysical Research Communications|February 27, 2007
Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cellsJohann Riedemann, Muhammad Sohail, Valentine M Macaulay
Biochemical and Biophysical Research Communications|February 20, 2007
The EGF receptor interacts with the type 1 IGF receptor and regulates its stabilityJohann Riedemann, Megumi Takiguchi, Muhammad Sohail, et al.
Immunologic Research|May 30, 2024
Highlighting the role of CD44 in cervical cancer progression: immunotherapy's potential in inhibiting metastasis and chemoresistanceCayleigh de Sousa, Carla Eksteen, Johann Riedemann, et al.
Nucleic Acids Research|March 26, 2003
A simple and cost-effective method for producing small interfering RNAs with high efficacyMuhammad Sohail, Graeme Doran, Johann Riedemann, et al.
Cytokine & Growth Factor Reviews|December 5, 2025
Post COVID-19 pandemic Inflammatory Insights into Cancer: Consequences for immunotherapyCarla Eksteen, Lé-Chandré Asja, Atarah Rass, et al.
Cancer Gene Therapy|October 23, 2004
Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancerMark A Rochester, Johann Riedemann, Giles O Hellawell, et al.
Seminars in Oncology|June 12, 2025
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy responseCarla Eksteen, Johann Riedemann, Frederick H van der Merwe, et al.
The Journal of Biological Chemistry|February 27, 2003
The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcriptErin A Bohula, Amanda J Salisbury, Muhammad Sohail, et al.
BMC Cell Biology|May 17, 2011
Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein CGerrida M Uys, Amsha Ramburan, Benjamin Loos, et al.
Cancer Control : Journal of the Moffitt Cancer Center|June 17, 2024
A Review: Genetic Mutations as a Key to Unlocking Drug Resistance in Cervical CancerCarla Eksteen, Johann Riedemann, Atarah M Rass, et al.
Pageof 2